Drug targets for Cancer: JAK2

Drug Targets for Cancer: JAK2 and Cancer

Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells. Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed. The JAK/STAT signalling pathway provides an example of this paradigm in haematological malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clinically effective JAK2 inhibitors, such as ruxolitinib. It is now clear that many solid tumours also show activation of JAK/STAT signalling.

Drug Targets for Cancer: JAK2 related Products

Drug targets for cancer: JAK2 research reagents

Other vital drug targets for cancer likeJAK2:

Drug Targets for Cancer: JAK2 Related Reference

Thomas S J, et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours[J]. British journal of cancer, 2015, 113(3): 365-371.

Drug Targets for Cancer: JAK2 Related Information

Drug Targets for Cancer